|
| Press Releases |
|
 |
|
| Thursday, June 22, 2023 |
|
|
エーザイ、東京都文京区の2023年度認知症検診事業において「のうKNOW(R)」による脳の健康度測定を継続実施 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、東京都文京区(以下、文京区)が実施する2023年度認知症検診事業（以下、本事業）において、当社の認知機能のデジタルチェックツール「のうKNOW(R)」による脳の健康度測定が継続実施されることをお知らせします。 more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイ、米国FDA諮問委員会は全会一致でアルツハイマー病治療薬「LEQEMBI(R)」（レカネマブ）の臨床上のベネフィットを支持 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、米国食品医薬品局（FDA）の末梢・中枢神経系薬物諮問委員会（Peripheral and Central Nervous System Drugs Advisory Committee、以下 本諮問委員会）が開催され、「LEQEMBI(R)」注射100 mg/mL溶液（一般名：レカネマブ）の臨床第III相Clarity AD検証試験の結果が、本剤の臨床上のベネフィットを示すエビデンスであることが、全会一致で支持されましたのでお知らせします。 more info >> |
|
| Thursday, June 8, 2023 |
|
|
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea |
| This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries. more info >> |
|
|
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、韓国において早期アルツハイマー病に係る適応で新薬承認を申請 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、エーザイが抗アミロイドβ（Aβ）プロト フィブリル*抗体レカネマブ（一般名、米国ブランド名：「LEQEMBI(R)」）について、脳内アミロイド病理が確認された早期アルツハイマー病（アルツハイマー病（AD）による軽度認知障害および軽度認知症）に係る適応で、韓国食品医薬品安全処（MFDS）に新薬承認申請を行いましたのでお知らせします。 more info >> |
|
| Friday, June 2, 2023 |
|
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
| Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
| Thursday, May 25, 2023 |
|
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
| Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
| Wednesday, May 24, 2023 |
|
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
|
米国臨床腫瘍学会年次総会におけるエーザイのがん領域の製品・開発品に関する発表について |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2023年6月2日から6日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2023 ASCO Annual Meeting）において、当社のがん領域における製品・開発品の様々ながん種における最新知見を発表することをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
HER Courage Leaders Summit 2025: Expanding Women's Leadership Across ASEAN
Mar 17, 2025 16:00 HKT/SGT
|
|
|
Brawijaya University Lecturer Develops IoT-based Chicken Coop Monitoring System
Mar 17, 2025 16:00 HKT/SGT
|
|
|
Future of airport operations to take centre stage at inter airport Southeast Asia conference
Mar 17, 2025 11:00 HKT/SGT
|
|
|
アリックスパートナーズ、自動車業界が今年最もディスラプションに直面する業界と考察
Mar 17, 2025 10:00: JST
|
|
|
Mitsubishi Electric Building Solutions Launches New Control Renewal Menu for Elevators Manufactured by Other Companies Overseas
Mar 17, 2025 11:00 JST
|
|
|
CITIC Resources Announces 2024 Annual Results, Revenue surges 148.3% to approximately HK$9.5 billion
Mar 17, 2025 09:56 HKT/SGT
|
|
|
中信資源公布2024年全年業績 收入大幅增長148.3%至約95.0億港元
Mar 17, 2025 09:45 HKT/SGT
|
|
|
中信资源公布2024年全年业绩 收入大幅增长148.3%至约95.0亿港元
Mar 17, 2025 09:31 HKT/SGT
|
|
|
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Mar 16, 2025 01:30 HKT/SGT
|
|
|
Habitat for Humanity offers up to US$40,000 in grants for innovative youth-led housing solutions in Asia-Pacific
Mar 16, 2025 00:30 HKT/SGT
|
|
|
SRKay Consulting Group Unveils Research on Why New-Shoring is Replacing Traditional Offshoring
Mar 16, 2025 00:25 HKT/SGT
|
|
|
Trust Swiftly Launches AI-Fighting Identity Verification Platform with Public Bounty Challenge
Mar 15, 2025 10:00: JST
|
|
|
Trust Swiftly Launches AI-Fighting Identity Verification Platform with Public Bounty Challenge
Mar 15, 2025 09:00 HKT/SGT
|
|
|
Approval in Principle (AiP) for the Basic Design of a Large Ammonia-Fueled Ammonia Carrier Obtained from Classification Society
Mar 14, 2025 18:37 JST
|
|
|
Probowangi Toll Road Package 3 Reaches 74.9% Completion, WIKA Supports Logistics Efficiency and National Connectivity
Mar 14, 2025 17:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
